Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
about
Antituberculosis therapy for 2012 and beyondDiagnosis & treatment of tuberculosis in HIV co-infected patients.Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeClinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnessesPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsModelling HIV and MTB co-infection including combined treatment strategiesComplications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosisAnti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control studyDevelopment of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrateEarly versus Delayed Antiretroviral Therapy for HIV and Tuberculosis Co-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsHIV and Tuberculosis: a Deadly Human SyndemicPopulation pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIsImmunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand.Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings.Effect of pulmonary tuberculosis on mortality in patients receiving HAART.Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.Treatment Options for HIV-Associated Tuberculosis.Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort studyRandomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndromeHIV-Associated Tuberculosis.Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.Extensively drug-resistant tuberculosis: a new face to an old pathogen.Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Cyto-genotoxicity Assessment of Potential Anti-tubercular Drug Candidate Molecule-trans-cyclohexane-1, 4-diamine Derivative-9u in Human Lung Epithelial Cells A549.Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis.Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South AfricaThe role of delamanid in the treatment of drug-resistant tuberculosis.Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.Confronting the scientific obstacles to global control of tuberculosis.Unresolved antiretroviral treatment management issues in HIV-infected childrenAutophagy induction targeting mTORC1 enhances Mycobacterium tuberculosis replication in HIV co-infected human macrophagesSafety and effectiveness of HAART in tuberculosis-HIV co-infected patients in BrazilModel-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis.Severe paradoxical reaction requiring tracheostomy in a human immunodeficiency virus (HIV)-negative patient with cervical lymph node tuberculosis.Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections.
P2860
Q26829101-8F15CBC3-D24A-4B35-94D0-8A0B5F00D7FCQ26991633-39E787D5-E572-4187-947B-548DDC9F414CQ28088557-FAF99B46-0911-4607-B081-3F19D7A8C048Q28474814-AB2FA75D-F092-4688-BCE0-6E6AA7F9FF71Q28478275-E1249F14-A7D8-40E9-BF6D-C340FE8FB9C6Q28485357-EBCABD7E-B689-4A82-9365-84110DA598BBQ28486096-B16279F1-9390-46E7-BA9E-E4CDAF3D7A3BQ28488142-B14958B6-09E6-4A70-86D4-5AEDE1114EFAQ28535627-08D4430A-82A5-4C58-AE5E-FD2A56AC25CDQ28547436-F33D612F-EF64-42AE-BE07-9A27FB776F49Q28749315-926E668D-E0EA-4375-8FB4-D27BDD8C0E7DQ30052157-7D925882-70B4-460D-903F-E0AC107B2456Q31041943-DD19BBB3-0E48-49F1-AA47-2BC3BB68A5BDQ33686938-DAEE7B62-3F6F-46BB-872A-1FD30DA63D01Q33754205-E8A91CCE-C35E-47C4-9C41-D3D5027901E6Q33764880-AA889F68-37DA-411B-B60E-692A868FD8DCQ33807615-B316D588-5FF0-451E-A8AA-1EFD284882B5Q33813097-C97B06FD-CFDC-4ED6-8605-F78750B9F3BAQ33894801-2610C579-BB4D-4DCC-B78F-A5F535775A36Q34130659-8F762577-9C85-4B47-97D0-127769A07D71Q34143510-88554258-7B17-40EA-AD72-94464D29DA80Q34298935-BCBF8115-BF00-414A-A360-F25BA34455C6Q34453677-07E011E2-A47F-47DB-8408-8463F0D0E7B4Q34996334-172464B4-919B-4521-BA97-02D3E6BE79E5Q35043048-26B799C4-3A06-4B71-B5A4-4BDD8AF524BBQ35153274-0480F143-7E52-4EF7-A648-CF6BE3F12749Q35336481-31A78009-ECEF-4F02-B213-6DCF0D058C42Q35613107-DE00FCED-E0D5-4C80-8862-0EA17E2A48A8Q35624245-49D4E7AC-F040-424B-B3F4-4D136A51D4DEQ35827839-83295A4A-353B-4255-9491-554D873CFED9Q36513366-46898376-1632-4579-BDCA-C92BDBD1AC3CQ36781481-BFC442C0-E1A4-4EA1-B2C3-0283E7B4A17FQ37006205-D9D14932-265C-4CCA-9D40-6802F356BCD4Q37020339-7C74E0FE-5FBB-4CDB-B12D-17EFA47CA7ADQ37026667-55CFFCD1-E3EA-456C-8A43-43ED2A327BCCQ37028388-D9AD74AF-7C14-4B61-9A2D-5B4817343238Q37041179-EF41418F-C5D9-47EE-BA51-E1589C6037EDQ37107955-7B6667DD-906F-418B-8624-DF66E5122DE3Q37113947-BDA61D66-8E0E-4BD7-896D-91785A6F241DQ37240766-B2568601-C433-4003-920E-E746B2A17D2D
P2860
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Complications of antiretrovira ...... itution inflammatory syndrome.
@en
type
label
Complications of antiretrovira ...... itution inflammatory syndrome.
@en
prefLabel
Complications of antiretrovira ...... itution inflammatory syndrome.
@en
P2860
P50
P356
P1476
Complications of antiretrovira ...... itution inflammatory syndrome.
@en
P2093
William J Burman
P2860
P304
P356
10.1086/518655
P407
P478
196 Suppl 1
P577
2007-08-01T00:00:00Z